Organization | Linyi Tumour Hospital

Linyi Tumour Hospital Report issue

Academic/Hospital Phase 1 Phase 3

Founded: Linyi China (1891)

Organization Overview

First Clinical Trial

2011

NCT01407822

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Linyi Cancer Hospital | Linyi Tumour Hospital

Active Ingredients

Drugs in Phase 3 Trials (11)

capecitabine (xeloda) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

Epimedium (2 trials)

erlotinib (tarceva) (1 trial)

gemcitabine (gemzar) (1 trial)

huachansu pian (1 trial)

paclitaxel (taxol) (1 trial)

rc48-adc (1 trial)

sorafenib (nexavar) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (1)

tisotumab vedotin (TIVDAK) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 12